Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.
Somatic mutations within the epidermal growth factor receptor (EGFR) kinase domain are detected in 10% to 30% of human non-small cell lung cancers and are correlated with striking clinical responses in a subset of patients treated with EGFR kinase inhibitors, such as gefitinib and erlotinib. Cell-based studies suggest that these mutant EGFRs promote increased autophosphorylating activity on a subset of EGFR COOH-terminal tyrosines and the consequent engagement of a subset of downstream effectors. Because EGFR function is regulated at multiple levels in vivo, and it is therefore difficult to assess the direct consequences of these mutations on EGFR enzyme function, we measured EGFR catalytic activity in in vitro kinase assays using purified recombinant proteins corresponding to the cytoplasmic domain of wild-type and two frequently detected EGFR mutants (DelL747-P753insS and L858R). Both mutants exhibit substantially increased autophosphorylating activity relative to wild-type EGFR, and they exhibit distinct reaction kinetics. In addition, the mutant kinases are more sensitive to kinase inhibition by gefitinib, which seems to reflect their increased drug affinity. These findings suggest that the altered signaling properties and drug sensitivity of these EGFR mutants that have been observed in vivo largely result from differences in the catalytic properties of the kinase. In addition, we find that the T790M secondary "drug resistance mutation" of EGFR, which frequently arises in relapsed patients that initially responded to treatment, confers enhanced kinase activity to primary activating EGFR alleles and may, therefore, be oncogenic in some contexts.
Mulloy
Roseann
R
Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA.
Ferrand
Audrey
A
Kim
Youngjoo
Y
Sordella
Raffaella
R
Bell
Daphne W
DW
Haber
Daniel A
DA
Anderson
Karen S
KS
Settleman
Jeffrey
J
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D016367:Baculoviridae / Q000235:genetics; D002384:Catalysis / Q000187:drug effects; D002478:Cells, Cultured; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000302:isolation & purification / Q000378:metabolism; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology / Q000235:genetics*; D050505:Mutant Proteins / Q000302:isolation & purification; D010770:Phosphotransferases / Q000378:metabolism; D011799:Quinazolines / Q000494:pharmacology*; D018411:Spodoptera; D013379:Substrate Specificity
D000970:Antineoplastic Agents; D050505:Mutant Proteins; D011799:Quinazolines; D010770:Phosphotransferases; D066246:ErbB Receptors; D000077156:Gefitinib